BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given an average recommendation of “Moderate Buy” by the twelve analysts that are presently covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $20.80.

A number of analysts have weighed in on BCRX shares. JPMorgan Chase & Co. initiated coverage on shares of BioCryst Pharmaceuticals in a report on Monday, July 13th. They set a “neutral” rating and a $12.00 price objective on the stock. Citizens Jmp raised their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Wall Street Zen cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Needham & Company LLC cut their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Finally, Royal Bank Of Canada increased their price objective on BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $8.98 on Monday. BioCryst Pharmaceuticals has a 52 week low of $6.00 and a 52 week high of $11.22. The company’s 50 day moving average is $9.30 and its two-hundred day moving average is $8.64. The company has a market cap of $2.28 billion, a PE ratio of -5.04 and a beta of 0.56.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The firm had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.20 EPS. As a group, equities research analysts expect that BioCryst Pharmaceuticals will post -2.58 EPS for the current year.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in BCRX. Royal Bank of Canada lifted its holdings in shares of BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of BioCryst Pharmaceuticals by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after acquiring an additional 8,517 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of BioCryst Pharmaceuticals by 49.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock worth $14,490,000 after acquiring an additional 640,704 shares during the period. Caxton Associates LLP acquired a new stake in BioCryst Pharmaceuticals in the first quarter valued at about $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of BioCryst Pharmaceuticals by 11.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock valued at $3,363,000 after purchasing an additional 47,355 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.